



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ




I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.




Signed

Dated 13 August 2001



official use



G2NDV00 E580498-1 D01298
P01/7700 0.00-0026727.8

0026727.8

Your reference
PCS10895PME- PROV

1 NOV 2000

Notes

Please type, or write in dark ink using CAPITAL letters. A prescribed fee is payable for a request for grant of a patent. For details, please contact the Patent Office (telephone 071-438 4700).

Rule 16 of the Patents Rules 1990 is the main rule governing the completion and filing of this form.

2 Do not give trading styles, for example, 'Trading as XYZ company', nationality or former names, for example, 'formerly (known as) ABC Ltd' as these are not required.

Warning

After an application for a Patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977 and will inform the applicant if such prohibition or restriction is necessary. Applicants resident in the United Kingdom are also reminded that under Section 23, applications may not be filed abroad without written permission unless an application has been filed not less than 6 weeks previously in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction revoked.

The
Patent
Office

Request for grant of a Patent Form 1/77

Patents Act 1977

1 Title of invention

MODULATION OF PDE11 ACTIVITY

- 1 Please give the title of the invention

2 Applicant's details

☒ First or only applicant

- 2a If you are applying as a corporate body please give:

Corporate name
PFIZER LIMITED

Country (and State of incorporation, if appropriate)
UNITED KINGDOM

- 2b If you are applying as an individual or one of a partnership please give in full:

Surname
Forenames

- 2c In all cases, please give the following details:

Address
RAMSGATE ROAD
SANDWICH
KENT

UK postcode CT13 9NJ
(if applicable)

Country UNITED KINGDOM
ADP number
(if known)

6892673001

2d, 2e and 2f:

If there are further applicants
please provide details on a separate
sheet of paper.

☒ **Second applicant (if any)**

2d If you are applying as a corporate body please give:

Corporate name

Country (and State of incorporation, if appropriate)

2e If you are applying as an individual or one of a partnership please give in full:

Surname

Forenames

2f In all cases, please give the following details:

Address

UK postcode
(if applicable)

Country

ADP number
(if known)

3

An address for service in the United
Kingdom must be supplied.

Please mark correct box

3 Address for service details

3a Have you appointed an agent to deal with your application?

Yes ☒ No ☐ ➔ go to 3b



Please give details below

Agent's name

P. M. ENGLAND

Agent's address

PFIZER LIMITED

RAMSGATE ROAD

SANDWICH

KENT

Postcode CT13 9NJ

Agent's ADP
number

3b If you have not appointed an agent please give a name and address in the United Kingdom to which all correspondence will be sent:

Name

Address

Postcode
ADP number
(if known)

Daytime telephone
number(if available)

3b:

If you have appointed an agent,
all correspondence concerning
your application will be sent to
the agent's United Kingdom
address.

4 Reference number

4 Agent's or applicant's
reference number
(if applicable)

PCS10895PME-PROV

5 Claiming an earlier application date

5 Are you claiming that this application be treated as having been filed on the date of filing of an earlier application?

Please mark correct box

Yes ☐ No ☒ ➡ go to 6

↓
please give details below

☐ number of earlier
application or patent
number

☐ filing date
(day month year)

☐ and the Section of the Patents Act 1977 under which you are claiming:

Please mark correct box

15(4) (Divisional) ☐ 8(3) ☐ 12(6) ☐ 37(4) ☐

6 Declaration of priority

6 If you are declaring priority from previous application(s), please give:

Country of filing	Priority application number (if known)	Filing date (day, month, year)
-------------------	---	-----------------------------------

6

If you are declaring priority from a PCT Application please enter 'PCT' as the country and enter the country code (for example, GB) as part of the application number.

Please give the date in all number format, for example, 31/05/90 for 31 May 1990.

7

The answer must be 'No' if:
 - any applicant is not an inventor
 - there is an inventor who is not an applicant, or
 - any applicant is a corporate body.

8

Please supply duplicates of claim(s), abstract, description and drawing(s).

7 Inventorship

7 Are you (the applicant or applicants) the sole inventor or the joint inventors?

Please mark the correct box

Yes ☐

No ☒ ➔

A statement of Inventorship on Patents Form 7/77 will need to be filed (see Rule 15).

8 Checklist

8a Please fill in the number of sheets for each of the following types of document contained in this application.

Continuation sheets for this Patents Form 1/77

Claim(s)

3

Description

35

Abstract

1

Drawing(s)

2 d2

8b Which of the following documents also accompanies the application?

Priority documents (please state how many)

Translation(s) of Priority documents (please state how many)

Patents Form 7/77 - Statement of Inventorship and Right to Grant (please state how many)

Patents Form 9/77 - Preliminary Examination/Search

Patents Form 10/77 - Request for Substantive Examination

9 Request

I/We request the grant of a patent on the basis of this application.

Signed

P. England

Date 31/10/2000

(day month year)

Please return the completed form, attachments and duplicates where requested, together with the prescribed fee to:

 The Comptroller
The Patent Office
Cardiff Road
NEWPORT
Gwent
NP9 1RH

The Comptroller
The Patent Office
25 Southampton Buildings
London
WC2A 1AY

Please mark correct box(es)

9

You or your appointed agent (see Rule 90 of the Patents Rules 1990) must sign this request.

Please sign here ➔

A completed fee sheet should preferably accompany the fee.

MODULATION OF PDE11 ACTIVITY

Field of the Invention

The present invention relates to genetically-modified non-human mammals and genetically-modified animal cells containing a functionally disrupted PDE11 gene. The invention also features methods of screening for agents that modulate PDE11 and methods of modulating cAMP and cGMP signal transduction in cells that express PDE11.

Background

Cyclic nucleotide phosphodiesterases (PDEs) catalyze the hydrolysis of cyclic nucleotides, such as the second messengers cAMP (cyclic adenosine 3'5'-monophosphate) and cGMP (cyclic guanine 3'5'-monophosphate). Thus, PDEs play a pivotal regulatory role in a wide variety of signal transduction pathways (Beavo, *Physiol. Rev.* 75: 725-48, 1995). For example, PDEs mediate processes involved in vision (McLaughlin et al., *Nat. Genet.* 4: 130-34, 1993), olfaction (Yan et al., *Proc. Natl. Acad. Sci. USA* 92: 9677-81, 1995), platelet aggregation (Dickinson et al. *Biochem. J.* 323: 371-77, 1997), aldosterone synthesis (MacFarland et al., *J. Biol. Chem.* 266: 136-42, 1991), insulin secretion (Zhao et al., *J. Clin. Invest.* 102: 869-73, 1998), T cell activation (Li et al., *Science* 283: 848-51, 1999), and smooth muscle relaxation (Boolell et al., *Int. J. Impot. Res.* 8: 47-52, 1996; Ballard et al., *J. Urol.* 159: 2164-71, 1998).

PDEs form a superfamily of enzymes that are subdivided into 11 major families (Beavo, *Physiol. Rev.* 75: 725-48, 1995; Beavo et al., *Mol. Pharmacol.* 46: 399-05, 1994; Soderling et al., *Proc. Natl. Acad. Sci. USA* 95: 8991-96, 1998; Fisher et al., *Biochem. Biophys. Res. Commun.* 246: 570-77, 1998; Hayashi et al., *Biochem. Biophys. Res. Commun.* 250: 751-56, 1998; Soderling et al., *J. Biol. Chem.* 273: 15553-58, 1998; Fisher et al., *J. Biol. Chem.* 273: 15559-64, 1998; Soderling et al., *Proc. Natl. Acad. Sci. USA* 96: 7071-76, 1999; and Fawcett et al., *Proc. Natl. Acad. Sci. USA* 97: 3702-07, 2000).

Each PDE family is distinguished functionally by unique enzymatic characteristics and pharmacological profiles. In addition, each family exhibits distinct tissue, cell, and subcellular expression patterns (Beavo et al., *Mol. Pharmacol.* 46: 399-405, 1994; Soderling et al., *Proc. Natl. Acad. Sci. USA* 95:

8991-96, 1998; Fisher et al., Biochem. Biophys. Res. Commun. 246: 570-77, 1998; Hayashi et al., Biochem. Biophys. Res. Commun. 250: 751-56, 1998; Soderling et al., J. Biol. Chem. 273: 15553-58, 1998; Fisher et al., J. Biol. Chem. 273: 15559-64, 1998; Soderling et al., Proc. Natl. Acad. Sci. USA 96: 7071-76, 1999; Fawcett et al.,
5 Proc. Natl. Acad. Sci. USA 97: 3702-07, 2000; Boolell et al., Int. J. Impot. Res. 8: 47-52, 1996; Ballard et al., J. Urol. 159: 2164-71, 1998; Houslay, Semin. Cell Dev. Biol. 9: 161-67, 1998; and Torphy et al., Pulm. Pharmacol. Ther. 12: 131-35, 1999).

Therefore, by administering a compound that selectively regulates the activity of one family or subfamily of PDE enzymes, it is possible to regulate cAMP and/or
10 cGMP signal transduction pathways in a cell- or tissue-specific manner.

PDE11 is one of the most recently described families of PDEs (Fawcett et al., Proc. Natl. Acad. Sci. USA 97: 3702-07, 2000, hereinafter "Fawcett, 2000," Yuasa et al., Biochem. Mol. Biol. MO:03041, July 20, 2000, hereinafter "Yuasa, 2000"). While it known to be expressed in, e.g., testis, skeletal muscle, kidney,
15 liver, various glandular tissue (e.g., pituitary, salivary, adrenal, mammary, and thyroid), pancreas, spinal cord, and trachea (Fawcett, 2000), little is known about PDE11 function. The present invention provides biological tools to study PDE11 function and methods to identify agents that regulate PDE11 activity for use in treating diseases and conditions that are linked to these PDE11 functions.

20

Summary of the Invention

The present invention features genetically-modified animal cells and genetically-modified non-human mammals containing a disrupted PDE11 gene, as well as assays for identifying PDE11 function in cells and tissues that express
25 PDE11, methods for identifying agents that modulate these PDE11 functions, and methods of treating or preventing diseases or conditions in mammals by modulating PDE11 function. For example, modulators of PDE11 activity are administered to a mammal to modulate spermatogenesis.

One aspect of the invention features a genetically-modified, non-human
30 mammal, wherein the modification results in a functionally disrupted phosphodiesterase 11 (PDE11) gene. Preferably, the mammal is heterozygous for the modification. More preferably, the mammal is homozygous for the modification. In other preferred embodiments, the mammal is a rodent, more preferably, a mouse.

In a second aspect, the invention provides a genetically-modified animal cell, wherein the modification comprises a functionally disrupted PDE11 gene. Preferably, the animal cell is heterozygous for the modification. More preferably, the cell is homozygous for the modification. In other preferred embodiments, the
5 cell is an embryonic stem (ES) cell, and/or the cell is human or murine.

The third aspect of the invention features a method of identifying an agent that modulates spermatogenesis, involving contacting an agent with a PDE11 polypeptide and measuring PDE11 activity, wherein a difference between the activity in the absence of the agent and in the presence of the agent is indicative
10 that the agent can modulate spermatogenesis. Preferably, the method identifies an agent that inhibits PDE11 activity for use in decreasing spermatogenesis.

In a related fourth aspect, the invention also provides a method of identifying an agent that modulates spermatogenesis, which includes contacting an agent with a cell that expresses a PDE11 polypeptide and measuring PDE11 activity or PDE11
15 expression, wherein a difference between the activity or expression in the absence of the agent and in the presence of the agent is indicative that the agent can modulate spermatogenesis.

The fifth aspect provides a method of modulating spermatogenesis in a mammal, the method comprising administering an agent that modulates PDE11
20 activity. Preferably, the agent administered reduces PDE11 activity and reduces spermatogenesis.

Featured in the sixth aspect is a method of modulating cAMP and/or cGMP-mediated signal transduction in a mammal in bladder urothelium and/or bladder nerve fibers, neurons, cardiac myocytes, vascular smooth muscle, and/or vascular
25 endothelial cells, which includes administering an agent that modulates PDE11 activity.

Those skilled in the art will fully understand the terms used herein in the description and the appendant claims to describe the present invention. Nonetheless, unless otherwise provided herein, the following terms are as
30 described immediately below.

A non-human mammal or an animal cell that is "genetically-modified" is heterozygous or homozygous for a modification that is introduced into the non-human mammal or animal cell, or into a progenitor non-human mammal or animal cell, by genetic engineering. The standard methods of genetic engineering that are

available for introducing the modification include homologous recombination, viral vector gene trapping, irradiation, chemical mutagenesis, and the transgenic expression of a nucleotide sequence encoding antisense RNA alone or in combination with catalytic ribozymes. Preferred methods for genetic modification are those which modify an endogenous gene by inserting a "foreign nucleic acid sequence" into the gene locus, e.g., by homologous recombination or viral vector gene trapping. A "foreign nucleic acid sequence" is an exogenous sequence that is non-naturally occurring in the gene. This insertion of foreign DNA can occur within any region of the PDE11 gene, e.g., in an enhancer, promoter, regulator region, noncoding region, coding region, intron, or exon. The most preferred method of genetic engineering is homologous recombination, in which the foreign nucleic acid sequence is inserted in a targeted manner either alone or in combination with a deletion of a portion of the endogenous gene sequence.

By a PDE11 gene that is "functionally disrupted" is meant a PDE11 gene that is genetically modified such that the cellular activity of the PDE11 polypeptide encoded by the disrupted gene is decreased in cells that normally express a wild type version of the PDE11 gene. When the genetic modification effectively eliminates all wild type copies of the PDE11 gene in a cell (e.g., the genetically-modified, non-human mammal or animal cell is homozygous for the PDE11 gene disruption or the only wild type copy of PDE11 gene originally present is now disrupted), then the genetic modification results in a reduction in PDE11 polypeptide activity as compared to an appropriate control cell that expresses the wild type PDE11 gene. This reduction in PDE11 polypeptide activity results from either reduced PDE11 gene expression (i.e., PDE11 mRNA levels are effectively reduced and produce reduced levels of PDE11 polypeptide) and/or because the disrupted PDE11 gene encodes a mutated polypeptide with reduced function or stability as compared to a wild type PDE11 polypeptide. Preferably, the activity of PDE11 polypeptide in the genetically-modified, non-human mammal or animal cell is reduced to 50% or less of wild type levels, more preferably, to 25% or less, and, even more preferably, to 10% or less of wild type levels. Most preferably, the PDE11 gene disruption results in non-detectable PDE11 activity.

By a "genetically-modified, non-human mammal" containing a functionally disrupted PDE11 gene is meant a non-human mammal that is originally produced, for example, by creating a blastocyst or embryo carrying the desired genetic

modification and then implanting the blastocyst or embryo in a foster mother for *in utero* development. The genetically-modified blastocyst or embryo can be made, in the case of mice, by implanting a genetically-modified embryonic stem (ES) cell into a mouse blastocyst or by aggregating ES cells with tetraploid embryos.

5 Alternatively, various species of genetically-modified embryos can be obtained by nuclear transfer. In the case of nuclear transfer, the donor cell is a somatic cell or a pluripotent stem cell, and it is engineered to contain the desired genetic modification that functionally disrupts the PDE11 gene. The nucleus of this cell is then transferred into a fertilized or parthenogenetic oocyte that is enucleated, the
10 embryo is reconstituted, and developed into a blastocyst. A genetically-modified blastocyst produced by either of the above methods is then implanted into a foster mother according to standard methods well known to those skilled in the art. A "genetically-modified, non-human mammal" includes all progeny of the mammals created by the methods described above, provided that the progeny inherit at least
15 one copy of the genetic modification that functionally disrupts the PDE11 gene. It is preferred that all somatic cells and germline cells of the genetically-modified mammal contain the modification. Preferred non-human animals that are genetically-modified to contain a disrupted PDE11 gene include rodents, such as mice and rats, cats, dogs, rabbits, guinea pigs, hamsters, sheep, pigs, and ferrets.

20 By a "genetically-modified animal cell" containing a functionally disrupted PDE11 gene is meant an animal cell, including a human cell, created by genetic engineering to contain a functionally disrupted PDE11 gene, as well as daughter cells that inherit the disrupted PDE11 gene. These cells may be genetically-modified in culture according to any standard method known in the art. As an
25 alternative to genetically modifying the cells in culture, non-human mammalian cells may also be isolated from a genetically-modified, non-human mammal that contains a PDE11 gene disruption. The animal cells of the invention may be obtained from primary cell or tissue preparations as well as culture-adapted, tumorigenic, or transformed cell lines. These cells and cell lines are derived, for example, from
30 endothelial cells, epithelial cells, islets, neurons and other neural tissue-derived cells, mesothelial cells, osteocytes, lymphocytes, chondrocytes, hematopoietic cells, immune cells, cells of the major glands or organs (e.g., testicle, liver, lung, heart, stomach, pancreas, kidney, and skin), muscle cells (including cells from skeletal muscle, smooth muscle, and cardiac muscle), exocrine or endocrine cells,

fibroblasts, and embryonic and other totipotent or pluripotent stem cells (e.g., ES cells, ES-like cells, and embryonic germline (EG) cells, and other stem cells, such as progenitor cells and tissue-derived stem cells). The preferred genetically-modified cells are ES cells, more preferably, mouse or rat ES cells, and, most
5 preferably, human ES cells.

By an "ES cell" or an "ES-like cell" is meant a pluripotent stem cell derived from an embryo, from a primordial germ cell, or from a teratocarcinoma, that is capable of indefinite self renewal as well as differentiation into cell types that are representative of all three embryonic germ layers.

10 By "PDE11 polypeptide activity" or "PDE11 polypeptide-like activity" or "PDE11 activity" is meant the hydrolysis of cAMP or cGMP by a polypeptide encoded by a PDE11 gene. Such activity in a cell can be modulated at the level of PDE11 expression (e.g., by changing the amount of polypeptide that is effectively present within a cell) or by modifying the particular functional characteristics of each
15 PDE11 polypeptide molecule (e.g., by changing the K_m of hydrolysis for the mutated polypeptide).

By "modulates" is meant increases or decreases (including a complete elimination).

By an agent that is "selective" for modulating PDE11 activity is meant an
20 agent that primarily effects PDE11 while producing little effect on another PDE at the same concentration of agent. For example, if an agent is selective for inhibiting PDE11, the IC50 of the agent for PDE11 is at least 20 fold, more preferably, at least 30 fold, even more preferably, at least 50 fold, and, even more preferably, at least 100 fold, lower in concentration as compared to the IC50 for one or more PDEs
25 from the group of PDEs 1-10. Preferably, the agent is selective for PDE11 as compared to PDE3, PDE4, PDE5, and/or PDE6, and, even more preferably, as compared to all of PDEs 1-10.

Other features and advantages of the invention will be apparent from the following detailed description and from the claims. While the invention is described
30 in connection with specific embodiments, it will be understood that other changes and modifications that may be practiced are also part of this invention and are also within the scope of the appendant claims. This application is intended to cover any equivalents, variations, uses, or adaptations of the invention that follow, in general, the principles of the invention, including departures from the present disclosure that

come within known or customary practice within the art, and that are able to be ascertained without undue experimentation. Additional guidance with respect to making and using nucleic acids and polypeptides is found in standard textbooks of molecular biology, protein science, and immunology (see, e.g., Davis et al., Basic
5 Methods in Molecular Biology, Elsevier Sciences Publishing, Inc., New York, NY, 1986; Hames et al., Nucleic Acid Hybridization, IL Press, 1985; Molecular Cloning, Sambrook et al., Current Protocols in Molecular Biology, Eds. Ausubel et al., John Wiley and Sons; Current Protocols in Human Genetics, Eds. Dracopoli et al., John Wiley and Sons; Current Protocols in Protein Science, Eds. John E.
10 Coligan et al., John Wiley and Sons; and Current Protocols in Immunology, Eds. John E. Coligan et al., John Wiley and Sons). All publications mentioned herein are incorporated by reference in their entireties.

Description of the Figures

15 Figure 1 shows a schematic depicting an exemplary PDE11 gene targeting or knockout (KO) construct which undergoes homologous recombination with a murine PDE11 sequence and deletes gene sequence corresponding to nucleotides 560-575 of the human cDNA sequence in which the ATG start site begins at position 57, replacing it with the LacZNeo sequence. The deleted portion of the
20 gene comprises sequence encoding the catalytic domain of PDE11. The sequences of the homology arms that flank the LacZ/Neo sequence are designated SEQ ID NO: 7 and SEQ ID NO: 8. SS refers to intron splice sites within the gene. pA refers to a polyadenylation signal.

Figure 2A shows an exemplary human PDE11 sequence (SEQ ID NOs: 1
25 and 2) used to generate PCR primers (SEQ ID NOs: 3 and 4) for use in obtaining the corresponding murine gene sequence by PCR amplification.

Figure 2B shows the murine PDE11 gene PCR product generated using the primers shown in Figure 2A. These sequences are examples of murine PDE11 sequences that can be used to design the homology arms of a PDE11 targeting
30 construct, as shown in Figure 1.

Detailed Description

The present invention features genetically-modified animal cells and genetically-modified non-human mammals containing a disrupted PDE11 gene, as

well as assays for identifying PDE11 function in the cells and tissues that normally express PDE11.

Based upon studies of genetically-modified mice homozygous for a PDE11 disruption (PDE11-/-), we have discovered that PDE11 plays a role in stimulating spermatogenesis. Accordingly, the present invention also provides methods for impacting or affecting, e.g., stimulating or inhibiting, spermatogenesis in a mammal by administering an agent that increases or decreases PDE11 activity, respectively.

1. Genetically-Modified Non-human Mammals and Animal Cells

The genetically-modified, non-human mammals and genetically-modified animal cells, including human cells, of the invention are heterozygous or homozygous for a modification that functionally disrupts the PDE11 gene. The animal cells may be derived by genetically engineering cells in culture, or, in the case of non-human mammalian cells, the cells may be isolated from genetically-modified, non-human mammals.

The PDE11 gene locus is functionally disrupted by one of the several techniques for genetic modification known in the art, including chemical mutagenesis (Rinchik, Trends in Genetics 7: 15-21, 1991, Russell, Environmental & Molecular Mutagenesis 23 (Suppl. 24) 23-29, 1994), irradiation (Russell, *supra*), transgenic expression of PDE11 gene antisense RNA, either alone or in combination with a catalytic RNA ribozyme sequence (Luyckx et al., Proc. Natl. Acad. Sci. 96: 12174-79, 1999; Sokol et al., Transgenic Research 5: 363-71, 1996; Efrat et al., Proc. Natl. Acad. Sci. USA 91: 2051-55, 1994; Larsson et al., Nucleic Acids Research 22: 2242-48, 1994) and, as further discussed below, the disruption of the PDE11 gene by the insertion of a foreign nucleic acid sequence into the PDE11 gene locus. Preferably, the foreign sequence is inserted by homologous recombination or by the insertion of a viral vector. Most preferably, the method of PDE11 gene disruption is homologous recombination and includes a deletion of a portion of the endogenous PDE11 gene sequence.

The integration of the foreign sequence functionally disrupts the PDE11 gene through one or more of the following mechanisms: by interfering with the PDE11 gene transcription or translation process (e.g., by interfering with promoter recognition, or by introducing a transcription termination site or a translational stop codon into the PDE11 gene); or by distorting the PDE11 gene coding sequence such that it no longer encodes a PDE11 polypeptide with normal function (e.g., by

inserting a foreign coding sequence into the PDE11 gene coding sequence, by introducing a frameshift mutation or amino acid(s) substitution, or, in the case of a double crossover event, by deleting a portion of the PDE11 gene coding sequence that is required for expression of a functional PDE11 protein).

5 To insert a foreign sequence into a PDE11 gene locus in the genome of a cell, the foreign DNA sequence is introduced by any suitable method well known in the art such as electroporation, calcium-phosphate precipitation, retroviral infection, microinjection, biolistics, liposome transfection, DEAE-dextran transfection, or transferrinfection (see, e.g., Neumann et al., EMBO J. 1: 841-845, 1982; Potter et al., Proc. Natl. Acad. Sci USA 81: 7161-65, 1984; Chu et al., Nucleic Acids Res. 15: 1311-26, 1987; Thomas and Capecchi, Cell 51: 503-12, 1987; Baum et al., Biotechniques 17: 1058-62, 1994; Biewenga et al., J. Neuroscience Methods 71: 67-75, 1997; Zhang et al., Biotechniques 15: 868-72, 1993; Ray and Gage, Biotechniques 13: 598-603, 1992; Lo, Mol. Cell. Biol. 3: 1803-14, 1983; Nickoloff et al., Mol. Biotech. 10: 93-101, 1998; Linney et al., Dev. Biol. (Orlando) 213: 207-16, 1999; Zimmer and Gruss, Nature 338: 150-153, 1989; and Robertson et al., Nature 323: 445-48, 1986). The preferred method for introducing foreign DNA into a cell is electroporation.

A. Homologous Recombination

20 The method of homologous recombination targets the PDE11 gene for disruption by introducing a PDE11 gene targeting vector into a cell containing a PDE11 gene. The ability of the vector to target the PDE11 gene for disruption stems from using a nucleotide sequence in the vector that is homologous to the PDE11 gene. This homology region facilitates hybridization between the vector and the endogenous sequence of the PDE11 gene. Upon hybridization, the probability of a crossover event between the targeting vector and genomic sequences greatly increases. This crossover event results in the integration of the vector sequence into the PDE11 gene locus and the functional disruption of the PDE11 gene.

25 As those skilled in the art will appreciate, general principles regarding the construction of vectors used for targeting are reviewed in Bradley et al. (Biotechnol. 10: 534, 1992). Two different exemplary types of vector can be used to insert DNA by homologous recombination: an insertion vector or a replacement vector. An insertion vector is circular DNA which contains a region of PDE11 gene homology with a double stranded break. Following hybridization between the homology

region and the endogenous PDE11 gene, a single crossover event at the double stranded break results in the insertion of the entire vector sequence into the endogenous gene at the site of crossover.

5 The more preferred vector to use for homologous recombination is a replacement vector, which is colinear rather than circular. Replacement vector integration into the PDE11 gene requires a double crossover event, i.e. crossing over at two sites of hybridization between the targeting vector and the PDE11 gene. This double crossover event results in the integration of vector sequence that is sandwiched between the two sites of crossover into the PDE11 gene and the
10 deletion of the corresponding endogenous PDE11 gene sequence that originally spanned between the two sites of crossover (see, e.g., Thomas and Capecchi et al., Cell 51: 503-12, 1987; Mansour et al., Nature 336: 348-52, 1988; Mansour et al., Proc. Natl. Acad. Sci. USA 87: 7688-7692, 1990; and Mansour, GATA 7: 219-227, 1990).

15 A region of homology in a targeting vector is generally at least 100 nucleotides in length. Most preferably, the homology region is at least 1-5 kilobases (Kb) in length. There is no demonstrated minimum length or minimum degree of relatedness required for a homology region. However, one skilled in the art will recognize that targeting efficiency for homologous recombination will
20 generally correspond with the length and the degree of relatedness between the targeting vector and the PDE11 gene locus. In the case where a replacement vector is used, and a portion of the endogenous PDE11 gene is deleted upon homologous recombination, an additional consideration is the size of the deleted portion of the endogenous PDE11 gene. If this portion of the endogenous PDE11
25 gene is greater than 1 Kb in length, then a targeting cassette with regions of homology that are longer than 1 Kb is recommended to enhance the efficiency of recombination. Further guidance regarding the selection and use of sequences effective for homologous recombination is described in the literature (see, e.g., Deng and Capecchi, Mol. Cell. Biol. 12: 3365-3371, 1992; Bollag et al., Annu. Rev. Genet. 23: 199-225, 1989; and Waldman and Liskay, Mol. Cell. Biol. 8: 5350-5357,
30 1988).

A wide variety of cloning vectors may be used as vector backbones in the construction of the PDE11 gene targeting vectors of the present invention, including pBluescript-related plasmids (e.g., Bluescript KS+11), pQE70, pQE60, pQE-9, pBS,

pD10, phagescript, phiX174, pBK Phagemid, pNH8A, pNH16a, pNH18Z, pNH46A, ptrc99a, pKK223-3, pKK233-3, pDR540, and pRIT5 PWLNEO, pSV2CAT, pXT1, pSG (Stratagene), pSVK3, PBPV, PMSG, and pSVL, pBR322 and pBR322-based vectors, pBM9, pBR325, pKH47, pBR328, pHc79, phage Charon 28, pKB11, 5 pKSV-10, pK19 related plasmids, pUC plasmids, and the pGEM series of plasmids. These vectors are available from a variety of commercial sources (e.g., Boehringer Mannheim Biochemicals, Indianapolis, IN; Qiagen, Valencia, CA; Stratagene, La Jolla, CA; Promega, Madison, WI; and New England Biolabs, Beverly, MA). However, any other vectors, e.g. plasmids, viruses, or parts thereof, may be used 10 for propagation as long as they are replicable and viable in the desired host. The vector may also comprise sequences which enable it to replicate in the host whose genome is to be modified. The use of such a vector can expand the interaction period during which recombination can occur, increasing the efficiency of targeting (see Molecular Biology, ed. Ausubel et al, Unit 9.16, Fig. 9.16.1).

15 The specific host employed for propagating the targeting vectors of the present invention is not critical. Examples include *E. coli* K12 RR1 (Bolivar et al., Gene 2: 95, 1977), *E. coli* K12 HB101 (ATCC No. 33694), *E. coli* MM21 (ATCC No. 336780), *E. coli* DH1 (ATCC No. 33849), *E. coli* strain DH5 α , and *E. coli* STBL2. Alternatively, hosts such as *C. cerevisiae* or *B. subtilis* can be used. The above- 20 mentioned hosts are available commercially (e.g., Stratagene, La Jolla, CA; and Life Technologies, Rockville, MD).

To create the targeting vector, a PDE11 gene targeting construct is added to an above-described vector backbone. The PDE11 gene targeting constructs of the invention have at least one PDE11 gene homology region. To make the PDE11 25 gene homology regions, a PDE11 gene-related sequence is used as a basis for producing polymerase chain reaction (PCR) primers. These primers are used to amplify the desired region of the PDE11 sequence by high fidelity PCR amplification (Mattila et al., Nucleic Acids Res. 19: 4967, 1991; Eckert and Kunkel 1: 17, 1991; and U.S. Pat. No. 4,683,202). The genomic sequence is obtained from 30 a genomic clone library or from a preparation of genomic DNA, preferably from the animal species that is to be targeted for PDE11 gene disruption. PDE11 gene-related sequences have been reported in, e.g., Fawcett, 2000, 2000 (human PDE11A1, GenBank Accession No. AJ251509), WO 00/40733 (human PDE11A1

and PDE11A2), and Yuasa, 2000 (human PDE11A3 and PE11A4, GenBank Accession No. AB036704 and AB038041).

Preferably, the targeting constructs of the invention also include an exogenous nucleotide sequence encoding a positive marker protein. The stable
5 expression of a positive marker after vector integration confers an identifiable characteristic on the cell without compromising cell viability. Therefore, in the case of a replacement vector, the marker gene is positioned between two flanking homology regions so that it integrates into the PDE11 gene following the double crossover event.

10 It is preferred that the positive marker protein is a selectable protein; the stable expression of such a protein in a cell confers a selectable phenotypic characteristic, i.e., the characteristic enhances the survival of the cell under otherwise lethal conditions. Thus, by imposing the selectable condition, one can isolate cells that stably express the positive selectable marker from other cells that
15 have not successfully integrated the vector sequence on the basis of viability. Examples of positive selectable marker proteins (and their agents of selection) include Neo (G418 or kanamycin), Hyg (hygromycin), HisD (histidinol), Gpt (xanthine), Ble (bleomycin), and Hprt (hypoxanthine) (see, e.g., Capecchi and Thomas, U.S. Pat. No. 5,464,764, and Capecchi, Science 244: 1288-92, 1989).

20 Other positive markers that may also be used as an alternative to a selectable marker include reporter proteins such as β -galactosidase, firefly luciferase, or green fluorescent protein (see, e.g., Current Protocols in Cytometry, Unit 9.5, and Current Protocols in Molecular Biology, Unit 9.6, John Wiley & Sons, New York, NY, 2000).

The above-described positive selection scheme does not distinguish
25 between cells that have integrated the vector by targeted homologous recombination at the PDE11 gene locus versus random, non-homologous integration of vector sequence into any chromosomal position. Therefore, when using a replacement vector for homologous recombination, it is also preferred to include a nucleotide sequence encoding a negative selectable marker protein.

30 Expression of a negative selectable marker causes a cell expressing the marker to lose viability when exposed to a certain agent (i.e., the marker protein becomes lethal to the cell under certain selectable conditions). Examples of negative selectable markers (and their agents of lethality) include herpes simplex virus thymidine kinase (gancyclovir or 1,2-deoxy-2-fluoro- α -d-arabinofuransyl-5-

iodouracil), Hprt (6-thioguanine or 6-thioxanthine), and diphtheria toxin, ricin toxin, and cytosine deaminase (5-fluorocytosine).

5 The nucleotide sequence encoding the negative selectable marker is positioned outside of the two homology regions of the replacement vector. Given this positioning, cells will only integrate and stably express the negative selectable marker if integration occurs by random, non-homologous recombination; homologous recombination between the PDE11 gene and the two regions of homology in the targeting construct excludes the sequence encoding the negative selectable marker from integration. Thus, by imposing the negative condition, cells
10 that have integrated the targeting vector by random, non-homologous recombination lose viability.

A combination of positive and negative selectable markers is a preferred selection scheme for making the genetically-modified non-human mammals and animal cells of the invention because a series of positive and negative selection
15 steps can be designed to more efficiently select only those cells that have undergone vector integration by homologous recombination, and, therefore, have a potentially disrupted PDE11 gene. Further examples of positive-negative selection schemes, selectable markers, and targeting constructs are described, for example, in U.S. Pat. No. 5,464,764, WO 94/06908, and Valancius and Smithies, Mol. Cell.
20 Biol. 11: 1402, 1991.

In order for a marker protein to be stably expressed upon vector integration, the targeting vector may be designed so that the marker coding sequence is operably linked to the endogenous PDE11 gene promoter upon vector integration. Expression of the marker is then driven by the PDE11 gene promoter in cells that
25 normally express PDE11 gene. Alternatively, each marker in the targeting construct of the vector may contain its own promoter that drives expression independent of the PDE11 gene promoter. This latter scheme has the advantage of allowing for expression of markers in cells that do not typically express the PDE11 gene (Smith and Berg, Cold Spring Harbor Symp. Quant. Biol. 49: 171,
30 1984; Sedivy and Sharp, Proc. Natl. Acad. Sci. (USA) 86: 227: 1989; Thomas and Capecchi, Cell 51: 503, 1987).

Exogenous promoters that can be used to drive marker gene expression include cell-specific or stage-specific promoters, constitutive promoters, and inducible or regulatable promoters. Non-limiting examples of these promoters

include the herpes simplex thymidine kinase promoter, cytomegalovirus (CMV) promoter/enhancer, SV40 promoters, PGK promoter, PMC1-neo, metallothionein promoter, adenovirus late promoter, vaccinia virus 7.5K promoter, avian beta globin promoter, histone promoters (e.g., mouse histone H3-614), beta actin promoter, neuron-specific enolase, muscle actin promoter, and the cauliflower mosaic virus 35S promoter (see, generally, Sambrook et al., *Molecular Cloning*, Vols. I-III, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989, and *Current Protocols in Molecular Biology*, John Wiley & Sons, New York, NY, 2000; Stratagene, La Jolla, CA).

- 10 To confirm whether cells have integrated the vector sequence into the targeted PDE11 gene locus, primers or genomic probes that are specific for the desired vector integration event can be used in combination with PCR or Southern blot analysis to identify the presence of the desired vector integration into the PDE11 gene locus (Erich et al., *Science* 252: 1643-51, 1991; Zimmer and Gruss, 15 *Nature* 338: 150, 1989; Mouellic et al., *Proc. Natl. Acad. Sci. (USA)* 87: 4712, 1990; and Shesely et al., *Proc. Natl. Acad. Sci. (USA)* 88: 4294, 1991).

B. Gene Trapping

- Another method available for inserting a foreign nucleic acid sequence into the PDE11 gene locus to functionally disrupt the PDE11 gene is gene trapping. 20 This method takes advantage of the cellular machinery present in all mammalian cells that splices exons into mRNA to insert a gene trap vector coding sequence into a gene in a random fashion. Once inserted, the gene trap vector creates a mutation that may functionally disrupt the trapped PDE11 gene. In contrast to homologous recombination, this system for mutagenesis creates largely random 25 mutations. Thus, to obtain a genetically-modified cell that contains a functionally disrupted PDE11 gene, cells containing this particular mutation must be identified and selected from a pool of cells that contain random mutations in a variety of genes.

- Gene trapping systems and vectors have been described for use in 30 genetically modifying murine cells and other cell types (see, e.g., Allen et al., *Nature* 333: 852-55, 1988; Bellen et al., *Genes Dev.* 3: 1288-1300, 1989; Bier et al., *Genes Dev.* 3: 1273-1287, 1989; Bonnerot et al., *J. Virol.* 66: 4982-91, 1992; Brenner et al., *Proc. Nat. Acad. Sci. USA* 86: 5517-21, 1989; Chang et al., *Virology* 193: 737-47, 1993; Friedrich and Soriano, *Methods Enzymol.* 225: 681-701, 1993; Friedrich

and Soriano, *Genes Dev.* 5: 1513-23, 1991; Goff, *Methods Enzymol.* 152: 469-81, 1987; Gossler et al., *Science* 244: 463-65, 1989; Hope, *Develop.* 113: 399-408, 1991; Kerr et al., *Cold Spring Harb. Symp. Quant. Biol.* 2: 767-776, 1989; Reddy et al., *J. Virol.* 65: 1507-1515, 1991; Reddy et al., *Proc. Natl. Acad. Sci. U.S.A.* 89: 6721-25, 1992; Skarnes et al., *Genes Dev.* 6: 903-918, 1992; von Melchner and Ruley, *J. Virol.* 63: 3227-3233, 1989; and Yoshida et al., *Transgen. Res.* 4: 277-87, 1995).

Promoter trap (5' trap) vectors contain, in 5' to 3' order, a splice acceptor sequence followed by an exon, which is typically characterized by a translation initiation codon and open reading frame and/or an internal ribosome entry site. In general, these promoter trap vectors do not contain promoters or operably linked splice donor sequences. Consequently, after integration into the cellular genome of the host cell, the promoter trap vector sequence intercepts the normal splicing of the upstream gene and acts as a terminal exon. Expression of the vector coding sequence is dependent upon the vector integrating into an intron of the disrupted gene in the proper reading frame. In such a case, the cellular splicing machinery splices exons from the trapped gene upstream of the vector coding sequence (Zambrowicz et al., WO 99/50426).

An alternative method for producing an effect similar to the above-described promoter trap vector is a vector that incorporates a nested set of stop codons present in, or otherwise engineered into, the region between the splice acceptor of the promoter trap vector and the translation initiation codon or polyadenylation sequence. The coding sequence can also be engineered to contain an independent ribosome entry site (IRES) so that the coding sequence will be expressed in a manner largely independent of the site of integration within the host cell genome. Typically, but not necessarily, an IRES is used in conjunction with a nested set of stop codons.

Another type of gene trapping scheme uses a 3' gene trap vector. This type of vector contains, in operative combination, a promoter region, which mediates expression of an adjoining coding sequence, the coding sequence, and a splice donor sequence that defines the 3' end of the coding sequence exon. After integration into a host cell genome, the transcript expressed by the vector promoter is spliced to a splice acceptor sequence from the trapped gene that is located downstream of the integrated gene trap vector sequence. Thus, the integration of

the vector results in the expression of a fusion transcript comprising the coding sequence of the 3' gene trap cassette and any downstream cellular exons, including the terminal exon and its polyadenylation signal. When such vectors integrate into a gene, the cellular splicing machinery splices the vector coding sequence upstream of the 3' exons of the trapped gene. One advantage of such vectors is that the expression of the 3' gene trap vectors is driven by a promoter within the gene trap cassette and does not require integration into a gene that is normally expressed in the host cell (Zambrowicz et al., WO 99/50426). Examples of transcriptional promoters and enhancers that may be incorporated into the 3' gene trap vector include those discussed above with respect to targeting vectors.

The viral vector backbone used as the structural component for the promoter or 3' gene trap vector may be selected from a wide range of vectors that can be inserted into the genome of a target cell. Suitable backbone vectors include, but are not limited to, herpes simplex virus vectors, adenovirus vectors, adeno-associated virus vectors, retroviral vectors, lentiviral vectors, pseudorabies virus, alpha-herpes virus vectors, and the like. A thorough review of viral vectors, in particular, viral vectors suitable for modifying nonreplicating cells and how to use such vectors in conjunction with the expression of an exogenous polynucleotide sequence, can be found in *Viral Vectors: Gene Therapy and Neuroscience Applications*, Eds. Caplitt and Loewy, Academic Press, San Diego, 1995.

Preferably, retroviral vectors are used for gene trapping. These vectors can be used in conjunction with retroviral packaging cell lines such as those described in U.S. Patent No. 5,449,614. Where non-murine mammalian cells are used as target cells for genetic modification, amphotropic or pantropic packaging cell lines can be used to package suitable vectors (Ory et al., Proc. Natl. Acad. Sci., USA 93: 11400-11406, 1996). Representative retroviral vectors that can be adapted to create the presently described 3' gene trap vectors are described, for example, in U.S. Pat. No. 5,521,076.

The gene trapping vectors may contain one or more of the positive marker genes discussed above with respect to targeting vectors used for homologous recombination. Similar to their use in targeting vectors, these positive markers are used in gene trapping vectors to identify and select cells that have integrated the vector into the cell genome. The marker gene may be engineered to contain an

IRES so that the marker will be expressed in a manner largely independent of the location in which the vector has integrated into the target cell genome.

Given that gene trap vectors will integrate into the genome of infected host cells in a fairly random manner, a genetically-modified cell having a disrupted
5 PDE11 gene must be identified from a population of cells that have undergone random vector integration. Preferably, the genetic modifications in the population of cells are of sufficient randomness and frequency such that the population represents mutations in essentially every gene found in the cell's genome, making it likely that a cell with a disrupted PDE11 gene will be identified from the population
10 (see Zambrowicz et al., WO 99/50426; Sands et al., WO 98/14614).

Individual mutant cell lines containing a disrupted PDE11 gene are identified in a population of mutated cells using, for example, reverse transcription and PCR to identify a mutation in a PDE11 gene sequence. This process can be streamlined by pooling clones. For example, to find an individual clone containing a disrupted
15 PDE11 gene, RT-PCR is performed using one primer anchored in the gene trap vector and the other primer located in the PDE11 gene sequence. A positive RT-PCR result indicates that the vector sequence is encoded in the PDE11 gene transcript, indicating that PDE11 gene has been disrupted by a gene trap integration event (see, e.g., Sands et al., WO 98/14614).

20 C. Temporal, Spatial, and Inducible PDE11 Gene Disruptions

In certain embodiments of the present invention, a functional disruption of the endogenous PDE11 gene occurs at specific developmental or cell cycle stages (temporal disruption) or in specific cell types (spatial disruption). In other
25 embodiments, the PDE11 gene disruption is inducible when certain conditions are present. A recombinase excision system, such as a Cre-Lox system, may be used to activate or inactivate the PDE11 gene at a specific developmental stage, in a particular tissue or cell type, or under particular environmental conditions.

Generally, methods utilizing Cre-Lox technology are carried out as described by Torres and Kuhn, *Laboratory Protocols for Conditional Gene Targeting*, Oxford
30 University Press, 1997. Methodology similar to that described for the Cre-Lox system can also be employed utilizing the FLP-FRT system. The FLP-FRT system and further guidance regarding the use of recombinase excision systems for conditionally disrupting genes by homologous recombination or viral insertion are provided, for example, in U.S. Pat. No. 5,626,159, U.S. Pat. No. 5,527,695, U.S.

Pat. No. 5,434,066, WO 98/29533, Orban et al., Proc. Nat. Acad. Sci. USA 89: 6861-65, 1992; O'Gorman et al., Science 251: 1351-55, 1991; Sauer et al., Nucleic Acids Research 17: 147-61, 1989; Barinaga, Science 265: 26-28, 1994; and Akagi et al., Nucleic Acids Res. 25: 1766-73, 1997. More than one recombinase system
5 can be used to genetically modify a non-human mammal or animal cell.

When using homologous recombination to disrupt the PDE11 gene in a temporal, spatial, or inducible fashion, using a recombinase system such as the Cre-Lox system, a portion of the PDE11 gene coding region is replaced by a targeting construct comprising the PDE11 gene coding region flanked by loxP sites.
10 Non-human mammals and animal cells carrying this genetic modification contain a functional, loxP-flanked PDE11 gene. The temporal, spatial, or inducible aspect of the PDE11 gene disruption is caused by the expression pattern of an additional transgene, a Cre recombinase transgene, that is expressed in the non-human mammal or animal cell under the control of the desired spatially-regulated,
15 temporally-regulated, or inducible promoter, respectively. A Cre recombinase targets the loxP sites for recombination. Therefore, when Cre expression is activated, the LoxP sites undergo recombination to excise the sandwiched PDE11 gene coding sequence, resulting in a functional disruption of the PDE11 gene (Rajewski et al., J. Clin. Invest. 98: 600-03, 1996; St.-Onge et al., Nucleic Acids
20 Res. 24: 3875-77, 1996; Agah et al., J. Clin. Invest. 100: 169-79, 1997; Brocard et al., Proc. Natl. Acad. Sci. USA 94: 14559-63, 1997; Feil et al., Proc. Natl. Acad. Sci. USA 93: 10887-90, 1996; and Kühn et al., Science 269: 1427-29, 1995).

A cell containing both a Cre recombinase transgene and loxP-flanked PDE11 gene can be generated through standard transgenic techniques or, in the
25 case of genetically-modified, non-human mammals, by crossing genetically-modified, non-human mammals wherein one parent contains a loxP flanked PDE11 gene and the other contains a Cre recombinase transgene under the control of the desired promoter. Further guidance regarding recombinase systems and specific promoters useful to temporally, spatially, or conditionally disrupt the PDE11 gene is
30 found, for example, in Sauer, Meth. Enz. 225: 890-900, 1993, Gu et al., Science 265: 103-06, 1994, Araki et al., J. Biochem. 122: 977-82, 1997, Dymecki, Proc. Natl. Acad. Sci. 93: 6191-96, 1996, and Meyers et al., Nature Genetics 18: 136-41, 1998.

An inducible disruption of the PDE11 gene can also be achieved by using a tetracycline responsive binary system (Gossen and Bujard, Proc. Natl. Acad. Sci. USA 89: 5547-51, 1992). This system involves genetically modifying a cell to introduce a Tet promoter into the endogenous PDE11 gene regulatory element and a transgene expressing a tetracycline-controllable repressor (TetR). In such a cell, the administration of tetracycline activates the TetR which, in turn, inhibits PDE11 gene expression and, therefore, functionally disrupts the PDE11 gene (St.-Onge et al., Nucleic Acids Res. 24: 3875-77, 1996, U.S. Patent No. 5,922,927).

The above-described systems for temporal, spatial, and inducible disruptions of the PDE11 gene can also be adopted when using gene trapping as the method of genetic modification, for example, as described, for example, in WO 98/29533.

D. Creating Genetically-Modified, Non-human Mammals and Animal Cells

The above-described methods for genetic modification can be used to functionally disrupt a PDE11 gene in virtually any type of somatic or stem cell derived from an animal. Genetically-modified animal cells of the invention include, but are not limited to, mammalian cells, including human cells, and avian cells. These cells may be derived from genetically engineering any animal cell line, such as culture-adapted, tumorigenic, or transformed cell lines, or they may be isolated from a genetically-modified, non-human mammal carrying the desired PDE11 genetic modification.

The cells may be heterozygous or homozygous for the disrupted PDE11 gene. To obtain cells that are homozygous for the PDE11 gene disruption (PDE11^{-/-}), direct, sequential targeting of both alleles can be performed. This process can be facilitated by recycling a positive selectable marker. According to this scheme the nucleotide sequence encoding the positive selectable marker is removed following the disruption of one allele using the Cre-Lox P system. Thus, the same vector can be used in a subsequent round of targeting to disrupt the second PDE11 gene allele (Abuin and Bradley, Mol. Cell. Biol. 16: 1851-56, 1996; Sedivy et al., T.I.G. 15: 88-90, 1999; Cruz et al., Proc. Natl. Acad. Sci. (USA) 88: 7170-74, 1991; Mortensen et al., Proc. Natl. Acad. Sci. (USA) 88: 7036-40, 1991; te Riele et al., Nature (London) 348: 649-651, 1990).

An alternative strategy for obtaining ES cells that are PDE^{-/-} is the homogenotization of cells from a population of cells that is heterozygous for the

PDE11 gene disruption (PDE11^{+/-}). The method uses a scheme in which PDE11^{+/-} targeted clones that express a selectable drug resistance marker are selected against a very high drug concentration; this selection favors cells that express two copies of the sequence encoding the drug resistance marker and are, therefore, homozygous for the PDE11 gene disruption (Mortensen et al., Mol. Cell. Biol. 12: 2391-95, 1992). In addition, genetically-modified animal cells can be obtained from genetically-modified PDE11^{-/-} non-human mammals that are created by mating non-human mammals that are PDE11^{+/-} in germline cells, as further discussed below.

Following the genetic modification of the desired cell or cell line, the PDE11 gene locus can be confirmed as the site of modification by PCR analysis according to standard PCR or Southern blotting methods known in the art (see, e.g., U.S. Pat. No. 4,683,202; and Erlich et al., Science 252: 1643, 1991). Further verification of the functional disruption of the PDE11 gene may also be made if PDE11 gene messenger RNA (mRNA) levels and/or PDE11 polypeptide levels are reduced in cells that normally express the PDE11 gene. Measures of PDE11 gene mRNA levels may be obtained by using reverse transcriptase mediated polymerase chain reaction (RT-PCR), Northern blot analysis, or *in situ* hybridization. The quantification of PDE11 polypeptide levels produced by the cells can be made, for example, by standard immunoassay methods known in the art. Such immunoassays include, but are not limited to, competitive and non-competitive assay systems using techniques such as radioimmunoassays, ELISA (enzyme-linked immunosorbent assay), "sandwich" immunoassays, immunoradiometric assays, gel diffusion precipitin reactions, immunodiffusion assays, *in situ* immunoassays (using colloidal gold, enzymatic, or radioisotope labels, for example), Western blots, 2-dimensional gel analysis, precipitation reactions, immunofluorescence assays, protein A assays, and immunoelectrophoresis assays.

Preferred genetically-modified animal cells are ES cells and ES-like cells. These cells are derived from the preimplantation embryos and blastocysts of various species, such as mice (Evans et al., Nature 129:154-156, 1981; Martin, Proc. Natl. Acad. Sci., USA, 78: 7634-7638, 1981), pigs and sheep (Notanianni et al., J. Reprod. Fert. Suppl., 43: 255-260, 1991; Campbell et al., Nature 380: 64-68, 1996) and primates, including humans (Thomson et al., U.S. Patent No.

5,843,780, Thomson et al., Science 282: 1145-1147, 1995; and Thomson et al., Proc. Natl. Acad. Sci. USA 92: 7844-7848, 1995).

These types of cells are pluripotent. That is, under proper conditions, they differentiate into a wide variety of cell types derived from all three embryonic germ layers: ectoderm, mesoderm and endoderm. Depending upon the culture conditions, a sample of ES cells can be cultured indefinitely as stem cells, allowed to differentiate into a wide variety of different cell types within a single sample, or directed to differentiate into a specific cell type, such as macrophage-like cells, neuronal cells, cardiomyocytes, adipocytes, smooth muscle cells, endothelial cells, skeletal muscle cells, keratinocytes, and hematopoietic cells, such as eosinophils, mast cells, erythroid progenitor cells, or megakaryocytes. Directed differentiation is accomplished by including specific growth factors or matrix components in the culture conditions, as further described, for example, in Keller et al., Curr. Opin. Cell Biol. 7: 862-69, 1995, Li et al., Curr. Biol. 8: 971, 1998, Klug et al., J. Clin. Invest. 98: 216-24, 1996, Lieschke et al., Exp. Hematol. 23: 328-34, 1995, Yamane et al., Blood 90: 3516-23, 1997, and Hirashima et al., Blood 93: 1253-63, 1999.

The particular embryonic stem cell line that is used for genetic modification is not critical; exemplary murine ES cell lines include AB-1 (McMahon and Bradley, Cell 62:1073-85, 1990), E14 (Hooper et al., Nature 326: 292-95, 1987), D3 (Doetschman et al., J. Embryol. Exp. Morph. 87: 27-45, 1985), CCE (Robertson et al, Nature 323: 445-48, 1986), RW4 (Genome Systems, St. Louis, MO), and DBA/1lacJ (Roach et al., Exp. Cell Res. 221: 520-25, 1995). Genetically-modified murine ES cells may be used to generate genetically-modified mice, according to published procedures (Robertson, 1987, *Teratocarcinomas and Embryonic Stem Cells: A Practical Approach*, Ed. E. J. Robertson, Oxford: IRL Press, pp. 71-112, 1987; Zijlstra et al., Nature 342: 435-438, 1989; and Schwartzberg et al., Science 246: 799-803, 1989).

Following confirmation that the ES cells contain the desired functional disruption of the PDE11 gene, these ES cells are then injected into suitable blastocyst hosts for generation of chimeric mice according to methods known in the art (Capecchi, Trends Genet. 5: 70, 1989). The particular mouse blastocysts employed in the present invention are not critical. Examples of such blastocysts include those derived from C57BL/6 mice, C57BL/6 Albino mice, Swiss outbred mice, CFLP mice, and MFI mice. Alternatively, ES cells may be sandwiched

between tetraploid embryos in aggregation wells (Nagy et al., Proc. Natl. Acad. Sci. USA 90: 8424-8428, 1993).

5 The blastocysts or embryos containing the genetically-modified ES cells are then implanted in pseudopregnant female mice and allowed to develop *in utero* (Hogan et al., *Manipulating the Mouse Embryo: A Laboratory Manual*, Cold Spring Harbor Laboratory, 1988; and *Teratocarcinomas and Embryonic Stem Cells: A Practical Approach*, E.J. Robertson, ed., IRL Press, Washington, D.C., 1987). The offspring born to the foster mothers may be screened to identify those that are chimeric for the PDE11 gene disruption. Generally, such offspring contain some
10 cells that are derived from the genetically-modified donor ES cell as well as other cells from the original blastocyst. In such circumstances, offspring may be screened initially for mosaic coat color, where a coat color selection strategy has been employed, to distinguish cells derived from the donor ES cell from the other cells of the blastocyst. Alternatively, DNA from tail tissue of the offspring can be
15 used to identify mice containing the genetically-modified cells.

The mating of chimeric mice that contain the PDE11 gene disruption in germ line cells produces progeny that possess the PDE11 gene disruption in all germ line cells and somatic cells. Mice that are heterozygous for the PDE11 gene disruption can then be crossed to produce homozygotes (see, e.g., U.S. Pat. No. 5,557,032,
20 and U.S. Pat. No. 5,532,158).

An alternative to the above-described ES cell technology for transferring a genetic modification from a cell to a whole animal is to use nuclear transfer. This method can be employed to make other genetically-modified, non-human mammals besides mice, for example, sheep (McCreath et al., Nature 29: 1066-69, 2000;
25 Campbell et al., Nature 389: 64-66, 1996; and Schnieke et al., Science 278: 2130-33, 1997) and calves (Cibelli et al., Science 280: 1256-58, 1998). Briefly, somatic cells (e.g., fibroblasts) or pluripotent stem cells (e.g., ES-like cells) are selected as nuclear donors and are genetically-modified to contain a functional disruption of the PDE11 gene. When inserting a DNA vector into a somatic cell to mutate the
30 PDE11 gene, it is preferred that a promoterless marker be used in the vector such that vector integration into the PDE11 gene results in expression of the marker under the control of the PDE11 gene promoter (Sedivy and Dutriaux, T.I.G. 15: 88-90, 1999; McCreath et al., Nature 29: 1066-69, 2000). Nuclei from donor cells which have the appropriate PDE11 gene disruption are then transferred to fertilized

or parthenogenetic oocytes that are enucleated (Campbell et al., Nature 380: 64, 1996; Wilmut et al., Nature 385: 810, 1997). Embryos are reconstructed, cultured to develop into the morula/blastocyst stage, and transferred into foster mothers for full term *in utero* development.

5 The present invention also encompasses the progeny of the genetically-modified, non-human mammals and genetically-modified animal cells. While the progeny are heterozygous or homozygous for the genetic modification that functionally disrupts the PDE11 gene, they may not be genetically identical to the parent non-human mammals and animal cells due to mutations or environmental
10 influences that may occur in succeeding generations at other loci in addition to the genetic modification presently described.

E. "Humanized" Non-human Mammals and Animal Cells

The genetically-modified non-human mammals and non-human animal cells of the invention containing a disrupted endogenous PDE11 gene can be further
15 modified to express the human PDE11 sequence (referred to herein as "humanized"). The human PDE11 sequence is disclosed, for example, in Fawcett, 2000, Phillips et al., WO 00/40733, and GenBank Accession No. AJ251509.

A preferred method for humanizing cells involves substituting the human PDE11 sequence for the endogenous PDE11 by homologous recombination. The
20 targeting vectors are similar to those traditionally used as knock out vectors with respect to the 5' and 3' homology arms and positive/negative selection schemes. However, the vectors also include sequences that, upon recombination, insert the human PDE11 coding sequence in exchange for the endogenous sequence, or affect base pair changes, codon substitutions, or exon substitutions, that modify the
25 endogenous sequence such that the sequence encodes the human PDE11 instead of the endogenous wild type sequence. Once homologous recombinants have been identified, it is possible to excise any inserted selection-based sequences (e.g., neo) by using Cre or Flp-mediated site directed recombination (Dymecki, Proc. Natl. Acad. Sci. 93: 6191-96, 1996).

30 It is preferred that the human PDE sequence be positioned directly downstream of the endogenous translation start site. This positioning preserves the endogenous temporal and spatial expression patterns of the PDE11 gene. The human sequence can comprise the whole genomic PDE11 sequence, or the full length human cDNA sequence with a polyA tail attached at the 3' end for proper

processing (Shiao et al., Transgenic Res. 8: 295-302, 1999). Further guidance regarding these methods of genetically modifying cells and non-human mammals to replace expression of an endogenous gene with its human counterpart is found, for example, in Sullivan et al., J. Biol. Chem. 272: 17972-80, 1997, Reaume et al., J. Biol. Chem. 271: 23380-88, 1996, and Scott et al., U.S. Pat. No. 5,777,194.

Another method for creating such "humanized" organisms is a multi-step process involving, first, the creation of PDE11^{-/-} embryos, and, second, the introduction of a transgene encoding the human sequence into the PDE11^{-/-} embryos.

10 F. Example - Generation of PDE11^{+/-} and PDE11^{-/-} Mice

Genetically-modified mouse ES cells (PDE11^{+/-}) were generated using the scheme shown in Fig. 1(DeltaGen, Menlo Park, CA). A partial cDNA sequence of the human PDE11 gene (Fig. 2A, SEQ ID NOs 1 and 2) was used to design oligonucleotide strands 7744 and 7745 as shown below.

15 Oligonucleotide 7744 - 5' TTTCTGTACCATCCCCAGCTCCATG 3' (SEQ ID NO:3)
Oligonucleotide 7745 - 5' AAGGCAGCCAACATCCCTCTGGTGT 3' (SEQ ID NO:4)

PCR based amplification of mouse genomic DNA using the above primers generated the product representing the mouse PDE11 sequence shown in Fig. 2B (SEQ ID NOs 5 and 6). Based upon this genomic sequence, a targeting construct was created which contained two homology arms (each of 10 nucleotides in length) of SEQ ID NOs 7 and 8, and a LacZ-Neo sequence inserted between the arms, as shown in Fig. 1. DNA containing the targeting construct was inserted into the ES cells by electroporation. Integration of this construct into the murine PDE11 gene in ES R1 cells (Deng et al., Dev. Biol. 185: 42-54, 1997; Udy et al., Exp. Cell Res. 20 231: 296-301, 1997) resulted in the replacement of the nucleotides 27-42 of SEQ ID NOs 5 and 6 with the LacZ-Neo gene. ES cells that were neomycin resistant were analyzed by Southern blot to confirm disruption of a PDE11 gene. These targeted ES cells were then used for generation of chimeric mice by injecting the cells into blastocysts and implanting the blastocysts into pseudopregnant female mice 25 30 (Capecchi et al., Trends Genet. 5: 70, 1989, Hogan et al., *Manipulating the Mouse Embryo: A Laboratory Manual*, Cold Spring Harbor Laboratory, 1988; and *Teratocarcinomas and Embryonic Stem Cells: A Practical Approach*, E.J. Robertson, ed., IRL Press, Washington, D.C., 1987). Chimeric mice were then bred with C57BL/6 (Jackson Laboratories, Bar Harbor, ME) mice to create F1

PDE+/- heterozygotes, which were in turn bred to produce F2 PDE-/- homozygotic mice. The functional disruption of the PDE11 gene in the heterozygotes and homozygotes was confirmed by PCR and Southern blot analysis.

5 2. Characterization of PDE11 Function and Therapeutic Relevance

 Perturbations that modulate PDE11 activity or expression can be induced in cells, tissues, or mammals to determine whether PDE11 modulation produces a physiologically relevant effect or phenotype. One means of inducing such a perturbation is genetically modifying a non-human mammal or animal cell to disrupt
10 the PDE11 gene. Alternatively, an agent that modulates PDE11 activity or expression can be administered to determine its effect on a cell or tissue preparation, or on a mammal.

 A. Tissue Expression

 Guidance for determining which cells, tissues, or phenotypes to study with
15 respect to PDE11 function is found in the PDE11 expression pattern in species such as mice and humans. In addition to what has previously been described for human PDE11 expression in Fawcett, 2000, (i.e., testis, skeletal muscle, kidney, liver, various glandular tissue (e.g., pituitary, salivary, adrenal, mammary, and thyroid), pancreas, spinal cord, and trachea), we hereby disclose additional tissues
20 that express PDE11, and further characterize expression in the previously disclosed tissues.

 PDE11 expression patterns were determined in formalin-fixed, paraffin-embedded normal human tissues sectioned at a width of 5 μ m (Peterborough Hospital Cellular Pathology Services, Peterborough, UK), and paraformaldehyde-
25 fixed, paraffin-embedded normal mouse testis samples sectioned at 7 μ M (Cat. No. 69584-3, Novagen, Madison, WI). The immobilised sections were dewaxed by washing in xylene (5 min.), absolute alcohol (5 min.), and then industrial methylated spirits (5 min.) Afterwards the slides were washed for 5 min. in running water, then treated for antigen retrieval according to one of the following methods: 1) treated
30 with trypsin for 15 min. at 37°C (Cat. No. T7168, Sigma Chemicals, St. Louis, MO, 1 tablet/ml water), followed by another wash in running water; or 2) treated with target retrieval solution (Cat. No. S1700, DAKO Corp., Carpinteria, CA) using the steamer method as per manufacturer's instructions, followed by several washes in tris-buffered saline (TBS) (Cat. No. T6664, Sigma Chemicals, St. Louis, MO, 1 sachet/L

water). Samples were soaked in fresh TBS and treated with the components of one of two alternative immunohistochemical kits, as indicated below.

Samples were incubated with a primary rabbit anti-PDE11 antibody (1:500 or 1:1000 dilution, in TBS/5% nonfat milk for 60 min.) The primary antibody was
5 raised against the human PDE11A (GenBank Accession No. AJ251509) catalytic domain peptide sequence of SAIFDRNRKDELPRL (SEQ ID NO: 9) (Cambridge Research Biochemicals, Cleveland, UK). The antibody detection system included either: 1) an anti-rabbit secondary antibody conjugate to horseradish peroxidase (HRP) and a 3,3'-diaminobenzidine (DAB) chromogen solution (Cat. No. K4010,
10 DAKO EnVision™+ System, DAKO Corp.); or 2) an anti-rabbit secondary antibody conjugated to alkaline phosphatase (AP) (Cat. No.-AK5001, ABC-AP kit, Vector Laboratories, Burlingame, CA) and an AP substrate kit (Cat. No. SK-5100, Vector® Red, Vector Laboratories). The immunohistochemical procedures were conducted according to manufacturers' recommendations. Following incubation with the
15 chromogen, tissues were counterstained with hemotoxylin (Cat. No. H3401, Vector Laboratories). The samples were then rinsed in water and dipped 10 times (10X) in acid rinse (2% v/v glacial acetic acid), followed by 10X in water, 20X in Scott's tap water (Cat. No. 6769002, Shandon Scientific, Runcorn, UK), rinsed 3 min. in water, dehydrated, mounted in DPX (Cat No. 360294H, BDH Laboratory Supplies, Poole,
20 UK), and sealed with a coverslip.

Strong PDE11 antibody staining was demonstrated in the following cell types and structures: cardiac myocytes in all chambers of the heart; vascular smooth muscle cells in venules, veins, arterioles, and arteries (particularly in vessels of smaller diameter) and vascular endothelial cells; Schwann cells and
25 perineural cells (nerve and vascular staining often correlated in particular tissues, e.g., bladder, testis, and heart); nuclei of spermatogonia in the testis; amine precursor uptake and decarboxylation (APUD) enteroendocrine cells in the colon and rectal glands; neurons throughout the brain (moderate to strong staining), such as in the substantia nigra, amygdala, nucleus basalis, the area postrema, and in the
30 anterior pituitary (especially in the periphery of the lateral zones); alveolar macrophages in the lung; islet cells in the pancreas; rare cells in the red pulp of the spleen; in numerous adipocytes; in lymphoid tissue; and in samples from cancerous prostate, hyperplastic prostate, and skin with malignant melanoma.

Additional cell types and tissues that showed moderate to weak staining for PDE11 included the following: the bladder urothelium, especially the basal to transitional epithelial layers (in the cytoplasm and, especially, in the nuclei of cells); cells in the exocrine parenchyma; keratinocytes in the basal and prickly layers of the epidermis; the cortex, outer root sheath, and collagenous root sheath of the hair follicle; eccrine glands; occasional Purkinje cells in the cerebellum; ependymal cells, cells in the basal ganglia and striatum; ganglion cells in Auerbach's plexus and Meissner's plexus; synovial cells; hepatocytes; smooth muscle; pleural mesothelium; squamous cells in the vaginal mucosa; lobular and ductal epithelial cells in the breast; vascular and sinusoidal lining cells in the splenic red pulp; sebaceous glands; convoluted tubules and collecting ducts in the kidney; histiocytes, including myointimal histiocytes in atherosclerosis; and mast cells, plasma cells, lymphocytes, and granulocytes.

Further clarification of expression in skeletal muscle showed variable staining, with strong staining of the motor end plates in a few samples. Staining varied from weak to strong in the anterior tibialis myocytes, the extensor digitorum longus, the gastrocnemius, the soleus, and in the vastus lateralis.

In the testis, Leydig cells and cells underlying the basement membrane of the seminiferous tubules (probably fibroblasts) stained positively at a moderate to weak level. Some spermatogenic cells stained positive.

Murine tissue expression patterns of PDE11 demonstrated weak expression in testis in the germinal epithelium of the seminiferous tubules. This expression is particularly prevalent in the spermatocytes. Leydig cells and fibroblasts in the connective tissue surrounding the tubules were negative for PDE11 expression.

25 B. Identification of PDE11 Agonists and Antagonists

One type of screen to identify PDE11 agonists and antagonists is conducted *in vitro* using native enzymes isolated from tissue, or using recombinant enzymes expressed in transfected host cells, for example, Sf9 insect cells (Fawcett, 2000), yeast cells (Loughney et al., U.S. Pat. No. 5,932,465), or COS-7 cells (Yuasa, 2000). Preferably, the PDE enzyme is human.

PDE11 activity is measured, for example, as the rate of hydrolysis of an appropriate substrate, [^3H]cAMP or [^3H]cGMP. Agents that increase or decrease substrate hydrolysis are identified as PDE11 selective agonists (i.e., enhancers) or antagonists (i.e., inhibitors), respectively. This activity is measured, for example, by

scintillation proximity assay (SPA)-based methods (Fawcett, 2000; Phillips et al., WO 00/40733, and Thompson et al., *Biochem. 18*: 5228, 1979 (as modified using product code TRKQ7090/7100, Amersham Int'l Ltd., Buckhamshire, England)).

5 Briefly, samples containing the PDE11 enzyme are contacted with a cAMP or cGMP substrate (Sigma Chemical), a portion (e.g., $\frac{1}{4}$ to $\frac{1}{2}$) of which is ^3H labelled (Amersham). Reactions are conducted in, for example, microtiter plates (e.g., Microfluor® plates, Dynex Technologies, Chantilly, VA), and are terminated by the addition of yttrium silicate SPA beads (Amersham) containing excess unlabeled cyclic nucleotide. After the beads are allowed to settle in the dark, plates are read
10 by a microtiter plate reader (e.g., TopCount®, Packard, Meriden, CT).

PDE activity may also be assayed by detection of ^{32}P -phosphate released from ^{32}P -cAMP or ^{32}P -cGMP (as described, for example, in Loughney et al., *J. Biol. Chem. 271*: 796-806, 1996, and Loughney, U.S. Pat. No. 5,932,465), or using
15 antibodies to distinguish between the PDE substrates, cGMP or cAMP, and their hydrolyzed products (using, for example FlashPlate™ technology, NEN® Life Sciences Products, Boston, MA).

As an alternative to assaying PDE11 catalytic activity, agents can be identified as PDE11 agonists or antagonists if they indirectly modulate PDE11 catalytic activity, for example, via post-translational modification (e.g.,
20 phosphorylation), modulation of allosteric ligand binding (e.g., via the GAF domain (Fawcett, 2000)), or by binding to PDE11 themselves at either a catalytic or allosteric regulatory site. Agents that increase PDE11 catalytic activity via these mechanisms are identified as potential agonists; conversely, agents that decrease PDE11 catalytic activity via these mechanisms are potential PDE11 antagonists.
25 Methods for determining PDE11 phosphorylation and allosteric ligand binding are described in the literature (see, e.g., McAllister-Lucas et al., *J. Biol. Chem. 270*: 30671-79, 1995, and Corbin et al., *Eur. J. Biochem. 267*: 2760-67, 2000).

Examples of agents that are screened include, but are not limited to, nucleic acids (e.g., DNA and RNA), carbohydrates, lipids, proteins, peptides,
30 peptidomimetics, small molecules and other compounds. Agents can be selected individually for testing or as part of a library. These libraries are obtained using any of the numerous approaches in combinatorial library methods known in the art, and include: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the "one-bead

one-compound" library method; and synthetic library methods using affinity chromatography selection. The biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds (e.g., Lam, 1997, Anticancer Drug Des. 12:145; U.S. Patent No. 5,738,996; and U.S. Patent No. 5,807,683).

Examples of methods for the synthesis of molecular libraries can be found in the art, for example, in DeWitt et al., 1993, Proc. Natl. Acad. Sci. USA 90:6909, Erb et al., 1994, Proc. Natl. Acad. Sci. USA 91:11422, Zuckermann et al., 1994, J. Med. Chem. 37:2678, Cho et al., 1993, Science 261:1303, Carrell et al., 1994, Angew. Chem. Int. Ed. Engl. 33:2059, Carrell et al., 1994, Angew. Chem. Int. Ed. Engl. 33:2061, and Gallop et al., 1994, J. Med. Chem. 37:1233.

Individual agents or libraries of agents may be presented in solution (e.g., Houghten, 1992, Bio/Techniques 13:412-421), or on beads (Lam, 1991, Nature 354:82-84), chips (Fodor, 1993, Nature 364:555-556), bacteria (U.S. Patent No. 5,223,409), spores (Patent Nos. 5,571,698; 5,403,484; and 5,223,409), plasmids (Cull et al., 1992, Proc. Natl. Acad. Sci. USA 89:1865-1869) or phage (Scott and Smith, 1990, Science 249:386-390; Devlin, 1990, Science 249:404-406; Cwirla et al., 1990, Proc. Natl. Acad. Sci. USA 87:6378-6382; and Felici, 1991, J. Mol. Biol. 222:301-310).

The effects of the test agents on PDE11 enzymatic kinetics (e.g., V_{max} and K_m) are determined *in vitro*, for example, by measuring hydrolysis with a fixed concentration of PDE11 enzyme, a range of substrate concentrations (e.g., 0.10-10 μM), and a time course ranging from, for example, 5-60 minutes. Agents that increase V_{max} or decrease K_m are identified as agonists. Agents that inhibit PDE11 activity decrease V_{max} or increase K_m and, preferably, have IC_{50} values in the nanomolar range. Such IC_{50} determinations involve assaying a fixed amount of purified recombinant or native PDE11 in the presence of various inhibitor concentrations and a low substrate concentration (e.g., 0.1-1.0 μM). Values for samples exposed to inhibitors are converted to percent activity of an uninhibited control (100%) and plotted against inhibitor concentration to find the concentration at which 50% inhibition occurs (IC_{50}).

Preferably, the screen identifies PDE11 agonists and antagonists that are selective for a PDE11 enzyme. For example, a preferred agonist or antagonist is selective for PDE11 by at least 20 fold, more preferably, at least 30 fold, even more

preferably, at least 50 fold, and, most preferably, at least 100 fold, as compared one or more PDEs from the group of PDEs 1-10. Preferred agonists and antagonists are selective for PDE11 as compared to one or more of PDE3, PDE4, PDE5, and/or PDE6.

5 For example, fold selectivity of an antagonist with respect to PDE11 as compared to another PDE is determined by dividing the IC₅₀ value for the other PDE by the IC₅₀ value for PDE11. Fold selectivity comparisons may involve comparing PDE11 values to previously reported values for other PDEs, or testing the other PDE enzymes concurrently.

10 As an alternative to *in vitro* screens, compounds can be screened for PDE11 modulating effects in a cell-based, tissue-based, or whole animal based assay, using samples that express PDE11 endogenously or as a result of genetic engineering.

15 In addition to comparing such samples in the presence and absence of the agent, an additional negative control for such assays is testing the agent on an appropriately matched, genetically-modified, PDE11^{-/-} cell or tissue preparation or non-human mammal. Such samples can be used to verify whether or not any observed effect in PDE11^{+/+} samples is mediated by PDE11.

Example: Identification of PDE11 Antagonists

20 Agents known to inhibit PDE5 were tested to determine whether they also modulated PDE11 activity according to the method described, e.g., in Fawcett, 2000 and in Phillips et al., WO 00/40733. The IC₅₀ values of the agents for inhibiting PDE11 were compared to the IC₅₀ values for inhibiting PDEs 5-10. PDE5 was isolated from human corpus cavernosum; PDE6 was isolated from
25 bovine retina; and recombinant human PDEs 7-11 were produced by baculovirus expression in Sf9 cells (Fawcett, 2000, and Ballard et al., J. Urol. 159: 2164-71, 1998).

30 The agents tested included the following: sildenafil; UK-336,017 (IC₃₅₁; (6R,12aR)-6-(1,3-benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-pyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione; CAS number: 171488-01-0; see, also, WO 9519978), UK-227,786 (E4021; 1-[4-[(1,3-benzodioxol-5-yl)methyl]amino]-6-chloro-2-quinazolinyl]-4-piperidinecarboxylic acid, monohydrochloride; CAS number: 150452-21-4; see, also, WO 9307124); and UK-235,187 (6-Chloro-2-(1H-

imidazol-1-yl)-N-(phenylmethyl)-4-quinazolinamine, dihydrochloride; CAS number: 157863-31-5; see, also, EP 579496).

Compounds were dissolved in DMSO (4mM) and then diluted to 40 μ M in buffer B (20 mM Tris-HCl, pH 7.4, 5 mM $MgCl_2$ -hexahydrate, 2 mg/ml bovine serum albumin (BSA)) at 25°C (all components are available from Sigma Chemicals, St. Louis, MO). This 40 μ M solution was then serially diluted to prepare a half log dilution over at least 5 points. Samples of each range point (25 μ l) were plated in duplicate in microtiter plates (Microfluor® plates, Dynex Technologies, Chantilly, VA). Samples containing the PDE enzyme were then added to each well. Purified recombinant or native enzyme was diluted 1:500 in buffer B, and 25 μ l of this dilution was added to each well. (This amount of enzyme was sufficient to ensure a linear reaction over time and concentration.) The enzyme and compound samples were then pre-incubated for 15 minutes at room temperature.

Substrate was added to each plate in 50 μ l samples. Substrate consisted of 90 nM unlabelled cGMP (Sigma Chemicals), 48 nM 3H -GMP (Cat. No. RPNQ0150, Amersham International Ltd.) in buffer A (20 mM Tris-HCl, pH 7.4, 5 mM $MgCl_2$ hexahydrate) for a final cGMP concentration of 69 nM for PDE11 tests (the substrate concentration for the other PDEs tested was adjusted to be less than or equal to $1/3 K_m$). Following a 50 minute incubation at room temperature on a plate shaker set to ensure adequate mixing, the reaction was terminated by the addition of yttrium silicate SPA beads (Amersham) containing excess (3mM) unlabeled cGMP. The plate was then shaken for 15 minutes to ensure even mixing and then beads were allowed to settle for 30 minutes. Plates were read by a microtiter plate reader (TopCount® plate reader, TopCount protocol 50, Packard, Meriden, CT).

The agents' IC50 values for inhibiting PDE11 were compared to those for inhibiting PDEs 5-10. As shown in Table 1 below, PDE5 inhibitors UK-336,017 (IC351), UK-227,786 (E4021), and UK-235,187 demonstrated selectivity for inhibiting PDE11 when compared to PDEs 7-10 (IC-351 was also selective for PDE11 over PDE6). By contrast, the PDE5 inhibitor sildenafil was not selective for PDE11 when compared to any of PDEs 5-10.

Table 1

IC50							
Compound	PDE5	PDE6	PDE7	PDE8	PDE9	PDE10	PDE11
Sildenafil	3.5nM	37.5nM	21.3µM	29.8µM	2.61µM	9.80µM	2.73µM
UK-336,017 (IC351)	8.9nM	1.5µM	>100µM	>100µM	>100µM	>100µM	40nM
UK-227,786 (E4021)	32nM	4.7nM	>100µM	>100µM	>100µM	>100µM	721nM
UK-235,187	4.8nM	1.0µM	>100µM	>100µM	>100µM	>100µM	131nM

All results are the geometric mean of at least 3 determinations.

C. Phenotypic Characterization of PDE11^{-/-} and PDE11^{+/-} Mice

- 5 The genetically-modified PDE11^{-/-} and PDE11^{+/-} non-human mammals and animal cells of the invention that have reduced PDE11 polypeptide activity can be used to identify novel PDE11-mediated biological functions based upon the appearance of any abnormal phenotypes, for example, as related to spermatogenesis, NO-mediated bladder relaxation, and vasodilation. Any
- 10 abnormal phenotypes associated with decreased PDE11 activity establish a basis for identifying and developing PDE11-targeted therapeutics for treating PDE11-related diseases or conditions.

Example - PDE^{-/-} mice demonstrate reduced spermatogenesis.

- 15 Mice homozygous for the PDE gene disruption were compared to wild type mice to identify any abnormal phenotypes at the age of 6-8 weeks. Data was collected from physical examination, necropsy, histology, clinical chemistry, blood chemistry, body weight, organ weight, and the cytological evaluation of bone marrow. For these comparisons, six PDE^{-/-} mice (3 males and 3 females), and four PDE11^{+/+} wild-type mice (2 males and 2 females) were studied.

- 20 Histological studies revealed changes in the testes of male PDE11^{-/-} mice. These changes included reduced spermatogenesis, an increased sloughing of spermatogenic epithelial cells, a thinning of the spermatogenic epithelium, a decrease in average seminiferous tubule diameter, a degeneration of the epithelial cells lining the tubule, and increased sloughing of residual bodies. These PDE11
- 25 KO mice also demonstrated reduced epididymal sperm, increased multinucleate sperm precursors, and an increased appearance of cell fragments and proteinaceous debris. Other tissues examined were histologically normal. These other tissues included seminal vesicles, salivary gland, thymus gland, pituitary gland, thyroid gland, aorta, heart, liver, gallbladder, esophagus, caecum, colon,

rectum, bones, joint tissue, spinal cord, bone marrow, trachea, larynx, skeletal muscle, sciatic nerve, tongue, mammary gland, ovary, uterus, cervix, ocular tissue, and Harderian glands. No consistent or significant differences between the PDE11^{-/-} mice and control mice were revealed in terms of blood chemistry analysis, organ weight, or body weight.

The abnormal phenotype observed in PDE11^{-/-} male mice indicates that PDE11 is normally involved in spermatogenesis. Therefore, inhibiting or enhancing PDE11 activity in a male mammal decreases or increases spermatogenesis, respectively. The role of PDE11 in spermatogenesis is further confirmed by PDE11 expression in the germinal epithelium of the seminiferous tubules, particularly in spermatocytes, of wild type mice.

D. Identification of PDE11 Function Using PDE11 Agonists and Antagonists

Compounds identified as modulators of PDE11, more preferably, compounds that are identified as selective PDE11 modulators, can be administered to cells or tissue preparations that express PDE11, or to whole animals, to identify PDE11 function based upon changes that occur in response to compound administration.

For example, given PDE11 expression in bladder urothelium, it is a candidate as a regulator of nitric oxide (NO)-mediated inhibition of bladder and bladder nerve fiber excitability. This NO-mediated effect is described, e.g., in Ozawa et al., J. Urol. 162: 2211, 1999, Pandita et al., J. Urol. 545-550, 2000, and Burnett et al., Nat. Med. 3: 571-74, 1997. To characterize the role of PDE11 in bladder contractility, the effects of a PDE11 antagonist can be studied in a model of oxyhemoglobin-induced (Pandita, *supra*) or cyclophosphamide-induced (Ozawa, *supra*), bladder hyperactivity. Experimental animals (e.g., rats) are administered oxyhemoglobin (intravesically, Sigma Chemical) or cyclophosphamide (intraperitoneally) in combination with a PDE11 antagonist dissolved, e.g., in DMSO and diluted by an appropriate buffer. The PDE11 antagonist is administered by an appropriate route (e.g., intravesically, intraperitoneally, or intravenously).

PDE11 is identified as playing a role in regulating NO-mediated inhibition of bladder and bladder nerve fiber excitability in test animals if a PDE11 antagonist causes a decrease in neuronal firing in afferent neurons innervating the bladder, a decrease in bladder contraction frequency, a decrease in micturition pressure, and/or a decrease basal pressure, as compared to control animals not administered

the antagonist. The measures of bladder function are made according to standard methods described in the literature (e.g. Pandita (*supra*), and Ozawa (*supra*)). As an additional control to confirm that the observed effect was mediated by inhibiting PDE11, appropriately matched, genetically-modified non-human mammals
5 containing a disrupted PDE11 gene (preferably, PDE11-/-) may be tested.

When testing the effect of an agent that modulates PDE11 activity or expression, it is preferred to use tissue or cell samples that express human PDE11, such as those derived from human cell lines or from a primary human tissue preparation. Alternatively, such tissue or cell samples may be obtained from a
10 PDE11 humanized non-human mammal or animal cell. Similarly, one preferred test animal for PDE11 functional studies is a genetically-modified PDE11 humanized mammal.

E. Therapeutic Applications

Agents identified as modulating PDE11 activity can be used for therapeutic
15 purposes. Preferably, the agent is selective for PDE11 with respect to at least one other PDE (e.g. UK-336,017 (IC351), UK-227,786 (E4021), and UK-235,187 are selective for PDE11, as compared to PDEs 7-10), more preferably, the agent is selective for PDE11 with respect to at least one of PDE3, PDE4, PDE5, and/or PDE6 (e.g., UK-336,017 (IC-351 is selective for PDE11 as compared to PDE6).

20 Exemplary therapeutic applications are as follows: administering the agent to modulate spermatogenesis for use as either a male contraceptive (by decreasing PDE11 activity and decreasing spermatogenesis) or to increase male fertility (by stimulating PDE11 activity and stimulating spermatogenesis); and administering the agent to decrease PDE11 activity for the treatment of a hyperexcitable or overactive
25 bladder. Agents that modulate PDE11 activity may be administered by any appropriate route. For example, administration may be parenteral, intravenous, intra-arterial, subcutaneous, intramuscular, intracranial, intraorbital, ophthalmic, intraventricular, intracapsular, intraspinal, intracisternal, intraperitoneal, intranasal, aerosol, by suppositories, or oral administration.

30 When administering therapeutic formulations comprising an agent that modulates PDE11 activity, the formulations may be in the form of liquid solutions or suspensions, in the form of tablets or capsules, or in the form of powders, nasal drops, or aerosols. Methods well known in the art for making formulations are

PC 10895.DAM-Prov

found, for example, in Remington's Pharmaceutical Sciences (ed. Gennaro, Mack Publishing Co., Easton, PA, 18th ed., 1990).

Claims

1. A genetically-modified, non-human mammal, wherein the modification results in a functionally disrupted phosphodiesterase 11 (PDE11) gene.
5
2. The mammal of claim 1, wherein said mammal is heterozygous for said modification.
3. The mammal of claim 1, wherein said mammal is homozygous for said modification.
10
4. The mammal of claim 1, wherein said mammal is a rodent.
5. The rodent of claim 4, wherein said rodent is a mouse.
15
6. A genetically-modified animal cell, wherein the modification comprises a functionally disrupted PDE11 gene.
7. The animal cell of claim 6, wherein said cell is heterozygous for said modification.
20
8. The animal cell of claim 6, wherein said cell is homozygous for said modification.
9. The animal cell of claim 6, wherein said cell is an embryonic stem (ES) cell.
25
10. The animal cell of claim 6, wherein said cell is human.
11. The animal cell of claim 6, wherein said cell is murine.
30
12. A method of identifying an agent that modulates spermatogenesis, said method comprising: contacting an agent with a PDE11 polypeptide and measuring PDE11 activity, wherein a difference between said activity in the absence of the

agent and in the presence of the agent is indicative that the agent can modulate spermatogenesis.

5 13. The method claim 12, wherein said agent inhibits PDE11 activity and is identified for use in decreasing spermatogenesis.

10 14. A method of identifying an agent that modulates spermatogenesis, said method comprising: contacting an agent with a cell that expresses a PDE11 polypeptide and measuring PDE11 activity or PDE11 expression, wherein a difference between said activity or expression in the absence of the agent and in the presence of the agent is indicative that the agent can modulate spermatogenesis.

15 15. A method of modulating spermatogenesis in a mammal, said method comprising administering an agent that modulates PDE11 activity.

16. The method of claim 15, wherein said agent reduces PDE11 activity and reduces spermatogenesis.

20 17. The method of claim 16, wherein said agent is UK-336,017 (IC-351), UK-227,786 (E4021), or UK-235,187.

25 18. A method of modulating cAMP and/or cGMP-mediated signal transduction in a mammal in bladder urothelium and/or bladder nerve fibers, neurons, cardiac myocytes, vascular smooth muscle, and/or vascular endothelial cells, said method comprising administering an agent that modulates PDE11 activity.

30 19. The method of claim 18, wherein said agent is UK-336,017 (IC-351), UK-227,786 (E4021), or UK-235,187.

20. A method of treating hypertension or incontinence, said method comprising administering an agent that modulates PDE11 activity.

PC 10895.DAM-Prov

21. The method of claim 20, wherein said agent is UK-336,017 (IC-351), UK-227,786 (E4021), or UK-235,187.

5

MODULATION OF PDE11 ACTIVITY

Abstract

The invention provides genetically-modified non-human mammals and genetically-modified animal cells containing a functionally disrupted PDE11 gene.

- 5 Also provided by the invention are methods of screening for agents that modulate PDE11 to modulate spermatogenesis, methods of treating mammals to modulate spermatogenesis, and methods of modulating cAMP and cGMP signal transduction in cells that express PDE11.

10




Figure 1






Figure 2

P-11 SEQUENCES: Human cDNA, Mouse PCR product, Oligonucleotides

Fig. 2 A HUMAN P-11 SEQUENCE (partial cDNA, both strands shown):

(SEQ ID NO:1) 5' <AAGGCAGCCACATCCCTCTGGTGTCTCAGAACTTGCATCGATGACATTTTGTGATGACTTTTCTCTCGACGTTGATGCCATGATCAGCTGCTCTCCGGATGTTTCATGGAGCTGGGGATGGTACAGAAA>3'
 (SEQ ID NO:2) 3' <TTCCGTCGGTTGTAGGGAGACACAGTCTTGAACGGTAGCTACTGTAAAGTAAACTACTGAAAAGAGAGCTGCAACTACGGTACTAGTGTCTCGACGAGAGGCGCTACAGTACCTCGACCCCTACCATGCTCTTT>5'
 (SEQ ID NO:3) Oligonucleotide 7744 (one strand): 5' <TTTCTGTACCATCCCGCAGCTCCATG>3'
 (SEQ ID NO:4) Oligonucleotide 7745 (one strand): 5' <AAGGCAGCCCAACATCCCTCTGGTGT>3'

PCR with oligonucleotides 7744 and 7745
 using mouse genomic DNA as the template.

Fig. 2 B MOUSE P-11 SEQUENCE (PCR product, both strands shown; divergence from human seq. in lower case):

(SEQ ID NO:5) 5' <TCGGAAGTGGCCATCGATGACATCCATTTTCATGACTTTTCCCTTCATGTTGATGCCATGATCAGAGCGCTCTaCGGATGTT>3'
 (SEQ ID NO:6) 3' <AGCCTTGACCGGTAGCTACTGTAGTAAAGCTACTGAAAAGGGAaCTaCAACTACGGTACTAGTGTCTCGGCGAGATGCCTACAA>5'

[illegible]